Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.63% is 52% below its 5-year average of 3.41%, near the low end of its 5-year range (0.00%–7.50%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.09% below its 12-month average of 2.33%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.63%.
DEBT TO ASSETS RATIO
1.63%
DEBT TO ASSETS RATIO AVG TTM
2.33%
DEBT TO ASSETS RATIO AVG 3Y
3.65%
DEBT TO ASSETS RATIO AVG 5Y
3.41%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-30.09%
CURRENT VS 3Y AVG
-55.37%
CURRENT VS 5Y AVG
-52.20%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+1529.25%
vs the sector median at left
Fulcrum Therapeutics, Inc.
Market Cap
$281.92M
Debt to Assets Ratio
1.63%
TTM Avg
2.33%
3Y Avg
3.65%
5Y Avg
3.41%
Market Cap
$282.98M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$284.38M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$286.20M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$276.57M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$274.61M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$272.17M
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$297.18M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.16M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $281.92M | 1.63% | 2.33% | 3.65% | 3.41% |
| Abeona Therapeutics Inc. (ABEO)vs › | $282.98M | 0.11% | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $284.38M | 0.01% | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $286.20M | 0.03% | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $276.57M | 0.04% | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.61M | 0.00% | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | 0.29% | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $297.18M | 0.00% | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | 0.01% | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | N/A | N/A | N/A |
Debt/Assets
1.6%
Debt/Equity
0.02
Current Ratio
31.35
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.63% |
| 2026-03-31 | 1.69% |
| 2025-12-31 | 1.76% |
| 2025-09-30 | 3.26% |
| 2025-06-30 | 3.31% |
| 2025-03-31 | 3.34% |
| 2024-12-31 | 3.31% |
| 2024-09-30 | 3.28% |
| 2024-06-30 | 3.28% |
| 2024-03-31 | 4.36% |
| 2023-12-31 | 4.20% |
| 2023-09-30 | 4.12% |
| 2023-06-30 | 4.05% |
| 2023-03-31 | 3.99% |
| 2022-12-31 | 5.92% |
| 2022-09-30 | 5.66% |
| 2022-06-30 | 7.50% |
| 2022-03-31 | 6.91% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.01% |
| 2020-09-30 | 0.02% |
| 2020-06-30 | 0.03% |
| 2020-03-31 | 0.05% |
| 2019-12-31 | 0.05% |
| 2019-09-30 | 0.04% |
| 2019-06-30 | 0.07% |
| 2019-03-31 | 0.06% |
| 2018-12-31 | 0.05% |
